Anbalcabtagene autoleucel (PD-1 and TIGIT knockdown CD19 CAR T-cell therapy) for relapsed or refractory LBCL: the CRC01-01 trial.
Won Seog Kim, Seok Jin Kim, Dok Hyun Yoon...
https://pubmed.ncbi.nlm.nih.gov/42284198/Actively Recruiting
Led by Curocell Inc. · Updated on 2026-07-01
91
Participants Needed
2
Research Sites
6 weeks
Total Duration
Researchers are studying the safety and effectiveness of CRC01, an investigational treatment, in adults with relapsed or refractory large B-cell lymphoma and B-cell Acute Lymphoblastic Leukemia. This multi-center phase III trial aims to assess how well CRC01 works and its tolerability in these patients who have not responded to previous therapies. Participants will first receive a conditioning chemotherapy regimen of fludarabine and cyclophosphamide. Following this, they will be given a single infusion of CRC01, which consists of chimeric antigen receptor CAR-transduced autologous T cells administered intravenously at specific target doses depending on the cohort. The study includes two cohorts with different dosing levels and will follow participants for up to five years to evaluate outcomes. During the trial, participants will be closely monitored through various assessments including laboratory tests, imaging, and evaluations of response rates, survival, and adverse events. Researchers will track the maximum tolerated dose in phase 1 and overall response and remission rates in phase 2. The study also involves long-term safety monitoring for adverse events, immunogenicity, and presence of replication-competent lentivirus, with participation lasting several years to fully assess the treatments effects.
CONDITIONS
Study of Efficacy and Safety of CRC01 in Adult Large B-cell Lymphoma and B-cell Acute Lymphoblastic Leukemia Patients
B
Bom-I Kwon, BSc
G
Gunsoo Kim, MSc
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Curocell Inc.
Lead Sponsor
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
Duration - Up to 5 days
Participants receive a chemotherapy regimen of fludarabine and cyclophosphamide to prepare the body for the investigational treatment.
Daily visits for chemotherapy administration
Duration - Single infusion with follow-up
Participants receive a single infusion of CRC01, which is a CAR T-cell therapy, at a target dose based on their cohort.
Monitoring visits following infusion
Duration - Up to 5 years
Participants are monitored for safety, response to treatment, and long-term outcomes including survival and adverse events over up to 5 years.
Periodic visits for assessments and tests
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Have more questions? Get in touch with our team for quick support
Won Seog Kim, Seok Jin Kim, Dok Hyun Yoon...
https://pubmed.ncbi.nlm.nih.gov/42284198/Young-Ho Lee, Hyeong Ji Lee, Hyung Cheol Kim...
https://pubmed.ncbi.nlm.nih.gov/34628052/Curocell Inc.
Lead Sponsor